Proteolytic Cleavage of Extracellular Secreted α-Synuclein via Matrix Metalloproteinases*

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Biological Chemistry

• Publication date

  2005-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1074/JBC.M503341200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of γ-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells

  2003cited by this paper
• Parkin Cleaves Intracellular α-Synuclein Inclusions via the Activation of Calpain*

  2003cited by this paper
• α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma

  2003cited by this paper
• Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions*

  2002cited by this paper
• Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease.

  2002cited by this paper
• Refolding of the catalytic and hinge domains of human MT1-mMP expressed in Escherichia coli and its characterization.

  2002cited by this paper
• S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death

  2002cited by this paper
• α-Synuclein is phosphorylated in synucleinopathy lesions

  2002cited by this paper
• Alpha-synuclein and the Lewy body disorders.

  2001cited by this paper
• Metalloproteinases in biology and pathology of the nervous system

  2001cited by this paper
• Induction of Neuronal Cell Death by Rab5A-dependent Endocytosis of α-Synuclein*

  2001cited by this paper
• Synucleinopathies: clinical and pathological implications.

  2001cited by this paper
• Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease.

  2000cited by this paper
• The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity

  2000cited by this paper
• Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects

  2000cited by this paper
• Alpha-synuclein and Parkinson's disease

  2000cited by this paper
• Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease.

  2000cited by this paper
• The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy

  2000cited by this paper
• Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain

  2000cited by this paper
• Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.

  2000cited by this paper
• Tissue Inhibitor of Metalloproteinases-2 Inhibits the 4-Aminophenylmercuric Acetate-Induced Activation and Autodegradation of the Free Promatrix Metalloproteinase-2

  1999cited by this paper
• Synucleins in synaptic plasticity and neurodegenerative disorders

  1999cited by this paper
• Matrix Metalloproteinases-3, -7, and -12, but Not -9, Reduce High Density Lipoprotein-induced Cholesterol Efflux from Human Macrophage Foam Cells by Truncation of the Carboxyl Terminus of Apolipoprotein A-I

  1999cited by this paper
• Stimulation of breast cancer invasion and metastasis by synuclein gamma.

  1999cited by this paper
• Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease.

  1999cited by this paper
• AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

  1998cited by this paper
• Laminin inhibits Aβ40 fibril formation promoted by apolipoprotein E4 in vitro

  1998cited by this paper
• Matrix metalloproteinases and diseases of the CNS.

  1998cited by this paper
• Protein Nitration in Parkinson's Disease

  1998cited by this paper
• Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil.

  1997cited by this paper
• α-Synuclein in Lewy bodies

  1997cited by this paper
• Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC.

  1997cited by this paper
• Hydrogen peroxide (H2O2) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts.

  1997cited by this paper
• Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease.

  1997cited by this paper
• Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia.

  1997cited by this paper
• Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

  1997cited by this paper
• The Rev Axis of HIV-1 and Its Associated Host Cofactors: A Viral Window onto the Workings of Eukaryotic Posttranscriptional RNA Processing.

  1996cited by this paper
• Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix.

  1996cited by this paper
• Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions

  1996cited by this paper
• Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40)

  1996cited by this paper
• NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation.

  1995cited by this paper
• Nitric oxide activates metalloprotease enzymes in articular cartilage.

  1995cited by this paper
• The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system

  1995cited by this paper
• Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization.

  1994cited by this paper
• The Family of Matrix Metalloproteinasesa

  1994cited by this paper
• Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

  1993cited by this paper
• A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor

  1993cited by this paper
• Purification and characterization of the human stromelysin catalytic domain expressed in Escherichia coli.

  1992cited by this paper
• Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes.

  1987cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

  1970cited by this paper

• Emerging role of microglia in inter-cellular transmission of α-synuclein in Parkinson’s disease

  2024cites this paper
• Integration of iPSC-Derived Microglia into Brain Organoids for Neurological Research

  2024cites this paper
• Role of non-neuronal cells in neurorepair: a focus on proteinopathy and neurodegeneration

  2024cites this paper
• α-Synuclein pathology as a target in neurodegenerative diseases

  2024cites this paper
• Augmented anti-cancer effect of hypoxia-inducible factor 2α (HIF2α)- targeting PT2385 delivered in α-synuclein-AuNP microcapsules for clear cell renal carcinoma mouse model

  2023cites this paper
• Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy

  2023cites this paper
• Truncation or proteolysis of α-synuclein in Parkinsonism.

  2023cites this paper
• Transthyretin has conformation-selective proteolytic activity against α-synuclein

  2023cites this paper
• Genetic lesions of the noradrenergic system trigger induction of oxidative stress and inflammation in the ventral midbrain.

  2022cites this paper
• Alpha synuclein processing by MMP-3 - implications for synucleinopathies.

  2022cites this paper
• The emerging role of furin in neurodegenerative and neuropsychiatric diseases

  2022cites this paper
• Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways

  2022cites this paper
• Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective

  2022cites this paper
• The Role of Proteolysis in Amyloidosis

  2022cites this paper
• The Role of Extracellular Matrix Components in the Spreading of Pathological Protein Aggregates

  2022cites this paper
• α-Synuclein at the Presynaptic Axon Terminal as a Double-Edged Sword

  2022cites this paper
• A method of purifying alpha-synuclein in E. coli without chromatography

  2021cites this paper
• Blood-brain barrier dysfunction as a potential therapeutic target for neurodegenerative disorders

  2021cites this paper
• A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies

  2021cites this paper
• Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications

  2021cites this paper
• Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives

  2021cites this paper
• Protein network analysis to prioritize key genes in amyotrophic lateral sclerosis

  2021cites this paper
• Quantification of allosteric communications in matrix metalloprotease-1 on alpha-synuclein aggregates and substrate-dependent virtual screening

  2021cites this paper
• Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors

  2021cites this paper
• Proteolytic α-Synuclein Cleavage in Health and Disease

  2021cites this paper
• Rab11-mediated recycling endosome role in nervous system development and neurodegenerative diseases

  2020cites this paper
• Deficiency of the serine peptidase Kallikrein 6 does not affect the levels and the pathological accumulation of a‐synuclein in mouse brain

  2020cites this paper
• Dendrimer-tesaglitazar conjugate induces a phenotype shift of microglia and enhances β-amyloid phagocytosis.

  2020cites this paper
• Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

  2020cites this paper
• The emerging role of α-synuclein truncation in aggregation and disease

  2020cites this paper
• Alpha-synuclein fragments trigger distinct aggregation pathways

  2020cites this paper
• Protein Quality Control Pathways at the Crossroad of Synucleinopathies

  2020cites this paper
• Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk

  2020cites this paper
• Involvement of Kallikrein-Related Peptidases in Nervous System Disorders

  2020cites this paper
• In Vivo Protein Complementation Demonstrates Presynaptic α-Synuclein Oligomerization and Age-Dependent Accumulation of 8-16-mer Oligomer Species.

  2019cites this paper
• The Impairments of α-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson’s Disease

  2019cites this paper
• Open questions on the nature of Parkinson’s disease: from triggers to spreading pathology

  2019cites this paper
• Matrix metalloproteinases in the CNS: interferons get nervous

  2019cites this paper
• Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson’s Disease

  2019cites this paper
• α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease

  2019cites this paper
• How is alpha‐synuclein cleared from the cell?

  2019cites this paper
• Metalloproteinases and their tissue inhibitors in Alzheimer’s disease and other neurodegenerative disorders

  2019cites this paper
• Microglia Response During Parkinson’s Disease: Alpha-Synuclein Intervention

  2018cites this paper
• Time‐Resolved NMR Analysis of Proteolytic α‐Synuclein Processing in vitro and in cellulo

  2018cites this paper
• Cell Biology and Pathophysiology of α-Synuclein.

  2018cites this paper
• Alpha Synuclein and Parkinson’s Disease

  2018cites this paper
• Exploring the putative role of kallikrein‐6, calpain‐1 and cathepsin‐D in the proteolytic degradation of α‐synuclein in multiple system atrophy

  2018cites this paper
• Release and uptake of pathologic alpha-synuclein

  2018cites this paper
• The effect of truncation on prion-like properties of α-synuclein

  2018cites this paper
• The effect of truncation on prion-like properties of (cid:2) -synuclein

  2018cites this paper
• Prion-like Propagation of α-Synuclein Is Regulated by the FcγRIIB-SHP-1/2 Signaling Pathway in Neurons.

  2018cites this paper
• Extracellular Interactions of Alpha-Synuclein in Multiple System Atrophy

  2018cites this paper
• SheddomeDB: the ectodomain shedding database for membrane-bound shed markers

  2017cites this paper
• Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides.

  2017cites this paper
• Endothelin‐converting enzymes degrade α‐synuclein and are reduced in dementia with Lewy bodies

  2017cites this paper
• New intracellular activities of matrix metalloproteinases shine in the moonlight.

  2017cites this paper
• Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.

  2017influential citation
• The multifaceted role of metalloproteinases in physiological and pathological conditions in embryonic and adult brains.

  2017cites this paper
• Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease

  2017cites this paper
• In vitro α-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains.

  2017cites this paper
• Alpha-synuclein in cerebrospinal fluid

  2017cites this paper
• α‐Synuclein Oligomers: A Study in Diversity

  2017cites this paper
• C-Terminal Truncated α-Synuclein Fibrils Contain Strongly Twisted β-Sheets

  2017cites this paper
• The Threshold Theory for Parkinson's Disease.

  2017cites this paper
• The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase‐2 on Extracellular α‐Synuclein Aggregates in Parkinsonian Models

  2016cites this paper
• Matrix Metalloproteinases in Non-Neoplastic Disorders

  2016cites this paper
• Post‐translational protein arginylation in the normal nervous system and in neurodegeneration

  2016cites this paper
• Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy

  2016cites this paper
• Combination therapies: The next logical Step for the treatment of synucleinopathies?

  2016cites this paper
• Caspase-1 clipping causes complications for α-synuclein

  2016cites this paper
• Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers

  2016cites this paper
• Sorting out release, uptake and processing of alpha‐synuclein during prion‐like spread of pathology

  2016cites this paper
• Extracellular α-Synuclein as a Target for Immunotherapy

  2016cites this paper
• Protein Partners of α‐Synuclein in Health and Disease

  2016cites this paper
• Cellular response of human neuroblastoma cells to α-synuclein fibrils, the main constituent of Lewy bodies.

  2016cites this paper
• Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein

  2016cites this paper
• KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species

  2016influential citation
• The Interplay between Alpha-Synuclein Clearance and Spreading

  2015cites this paper
• Effects of Aggregated Alpha-Synuclein on Cultured Neuronal Cells

  2015cites this paper
• Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases

  2015cites this paper
• The relation between α-synuclein and microglia in Parkinson's disease: Recent developments.

  2015cites this paper
• Mechanisms of Alpha-Synuclein Action on Neurotransmission: Cell-Autonomous and Non-Cell Autonomous Role

  2015cites this paper
• Assessing ethanol's actions in the suprachiasmatic circadian clock using in vivo and in vitro approaches.

  2015cites this paper
• Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome

  2015cites this paper
• 1 Matrix Metalloproteinases : From Structure to Function

  2015cites this paper
• Matrix Metalloproteinases: From Structure to Function

  2015cites this paper
• Transmission of Soluble and Insoluble &agr;-Synuclein to Mice

  2015cites this paper
• The Effects of Prolyl Oligopeptidase Inhibition in α-Synuclein Based Mouse Models of Parkinson's Disease

  2015cites this paper
• Region‐Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy

  2015cites this paper
• The future of blood‐based biomarkers for Alzheimer's disease

  2014cites this paper
• Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.

  2014cites this paper
• The clearance of misfolded proteins in neurodegenerative diseases by zinc metalloproteases: An inorganic perspective

  2014cites this paper
• The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity.

  2014cites this paper
• Matrix Metalloproteinase-3 Causes Dopaminergic Neuronal Death through Nox1-Regenerated Oxidative Stress

  2014cites this paper
• Resistance of naturally secreted α‐synuclein to proteolysis

  2014cites this paper
• Caspase-9 activation and Apaf-1 cleavage by MMP-3.

  2014cites this paper
• Review Article The future of blood-based biomarkers for Alzheimer's disease

  2014cites this paper
• Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation

  2014cites this paper
• Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

  2014cites this paper
• Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.

  2014cites this paper